Skip to content

Machine-based assessment of ocular parameters and its correlation with refractive changes, in children who were born prematurely with abnormal blood supply of retina and treated for the same

Ocular biometrics and Optical Coherence Tomography in Regressed Type 1 Retinopathy of Prematurity

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045281
Enrollment
32
Registered
2022-09-07
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H351- Retinopathy of prematurity

Interventions

None listed

Sponsors

Government Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children between 3-12 years of age with regressed type 1 ROP

Exclusion criteria

Exclusion criteria: 1. Patients with mental ailments which can hinder evaluation of visual acuity or slit-lamp examination 2. Patients with any macular pathology evident on ophthalmoscopy that might alter macular anatomy, such as macular folds, macular star, macular hole 3. Patients with other unrelated ocular conditions like trauma 4. Patients who have undergone surgery for unrelated ocular pathologies 5. Patients with spontaneously regressed ROP 6. Patients who are uncooperative for fixation and evaluation on Pentacam and/or OCT

Design outcomes

Primary

MeasureTime frame
To evaluate ocular biometry and macular abnormalities in children with regressed type 1 retinopathy of prematurityTimepoint: Baseline, 3 days, 21 days

Secondary

MeasureTime frame
To evaluate association of ocular biometry and macular abnormalities with refractive errorTimepoint: 3 months

Countries

India

Contacts

Public ContactDR SUBINA NARANG

Government Medical College and Hospital, Chandigarh

subina_navya@yahoo.com9646121587

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026